Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

Jan B. Vermorken, Fernando Rivera, Éva Remenár, +14

New England Journal of Medicine

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil, +213

The Lancet

Neoadjuvant TherapyChemotherapy Versus CetuximabMedicinePathologyHead And Neck Cancer +5

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, +107

The Lancet

MedicinePathologyHead And Neck CancerCancer TreatmentNeck Oncology +3

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini, +95

The Lancet Oncology

OncologyMedicineColorectal CancerPathologyUpfront Folfoxiri +6

Treatment of Advanced Squamous-Cell Carcinoma of the Head and Neck with Alternating Chemotherapy and Radiotherapy

Marco Merlano, Vito Vitale, Riccardo Rosso, +22

New England Journal of Medicine

Five-Year Update of a Randomized Trial of Alternating Radiotherapy and Chemotherapy Compared With Radiotherapy Alone in Treatment of Unresectable Squamous Cell Carcinoma of the Head and Neck

Marco Merlano, Marco Benasso, Renzo Corvò, +7

JNCI Journal of the National Cancer Institute

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

Lisa Licitra, Fernando Rivera, Éva Remenár, +10

Annals of Oncology

MedicinePathologyExtreme StudyFirst-line TreatmentHead And Neck Cancer +6

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

Fernando Rivera, Andrzej Kawecki, Sylvie Rottey, +11

Annals of Oncology

Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. The final report of a randomized trial

Marco Merlano, Renzo Corvò, G Margarino, +19

Cancer

Neoadjuvant TherapyMetronomic ChemotherapyCt. CtRadiation MedicineOncology +16

Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study

Marco Merlano, Elvio Russi, Marco Benasso, +12

Annals of Oncology

Advanced HeadNeck CancerRadiation TherapyMedicineCisplatin-based Chemoradiation +8